Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Lung Cancer Video Library - Spanish Language: Video #41 Molecular Marker Testing for Advanced NSCLC
Author
Denise Brock
 
 

 

We are pleased to continue this series of informational videos for our Spanish speaking community.  GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance.  In this 41st video for the Spanish lung cancer video library, Dr. Santana-Davila joined GRACE to discuss molecular marker testing for advanced NSCLC.


 

 

Marcador Molecular para Estadio Avanzado de Cancer de Células no Pequeñas

Molecular Marker Testing for Advanced NSCLC

 

Assistant Professor of Medicine
University of Washington Seattle Cancer Care Alliance
Seattle, Washington

 

Spanish TRANSCRIPT

Cuando tratamos a un paciente en estadio tres lo que esperamos es curar al paciente, desafortunadamente esto solo se lleva en el 20 al 25% de los casos y en la mayoría de los pacientes el cancer aparece de regreso. Algo que hacemos comúnmente es la terapia de consolidación, que es dar más quimioterapia después de la quimioterapia y radiación. Para escoger si se da terapia de consolidación o no es según el régimen se haya escogido. Si el régimen incluyo carboplatino y paclitaxel se le da dos ciclos más de quimioterapia después de la radiación. Cuando la quimioterapia no incluye éste último, la ventaja de dar más ciclos de quimioterapia es controversial y se debe de discutir entre el paciente y el doctor.


  

English TRANSCRIPT

When we treat a patient in stage three we hope to cure the patient, but that only happens in about 20 to 25% of them and in most cases cancer comes back. Something we commonly use is consolidation therapy in which we give more chemotherapy after the one used in the chemotherapy and radiation therapy. Choosing if consolidation therapy is the best option is based on the regimen used. If the regimen included carboplatin and paclitaxel, we will give two more chemotherapy cycles after the radiation is over. When the chemotherapy did not include paclitaxel, the benefits of giving more chemotherapy are controversial and you have to discuss it with your doctor.

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora